PTL-303

Pacific's other product candidate, PTL-303, is a combination of drugs that have been approved for use in Japan. This combination has a wide range of uses including, treating, preventing and reducing disorders of progressive scarring in humans.

The composition, including a cytokine modifier and anti-oxidant which is a precursor of Glutathione, was investigated for its antifibrotic activity by employing two In Vitro collagen synthesis assays. These experiments showed that the combination PTL-303 brings about substantial synergistic and super-additive anti-fibrotic effects in a TGF-β1 mediated collagen synthesis assay.

The composition can be administered in any convenient manner, such as orally, by inhalation, rectally, by injection , and may be formulated for topical or intra-venous administration.

A provisional patent titled: "Composition and Method for Treating Fibrosis" was filed with the United States patent office on October 29, 2008. A PCT application covering the technology of PTL-303 was filed October, 2009.